Effect of XXXX reductase inhibition on nerve conduction velocity and @entity616 in experimental @entity6 .

@entity8371 @entity8580 @entity6 @entity63 @entity3839 @entity3650 @entity35 @entity10916 @entity616
The relationships between nerve @entity8371 levels and both nerve conduction velocity (NCV) and @entity616 ( @entity616 ) in @entity3839 -induced @entity6 @entity35 were examined in two studies. In the first study, sciatic NCV and @entity616 of the tail nerve, assessed by measuring the time to disappearance of the nerve action potential after the tail was rendered @entity63 , were measured in nondiabetic @entity35 , untreated @entity6 @entity35 , and @entity6 @entity35 given Statil, an @entity3650 reductase inhibitor (ARI). Sciatic NCV was lower in the untreated @entity6 animals than in control animals (P less than .05), and @entity616 of the tail nerve was greater (P less than .001). Treatment with the ARI completely prevented the slowing of NCV but had no significant effect on the increase in @entity616 . In the second study, similar groups of @entity35 were treated with either @entity10916 , insulin, or @entity8580 . Sciatic NCV was lower in the untreated @entity6 @entity35 than in the nondiabetic @entity35 (P less than .001). In @entity6 @entity35 treated with the ARI and in those treated with insulin, NCV was greater than in the untreated @entity6 @entity35 (P less than .05 and P less than .001, respectively) and was not significantly different from the nondiabetic @entity35 . NCV in the @entity8580 -treated @entity35 was not significantly different from that in the untreated @entity6 @entity35 . @entity616 was assessed by measuring the decline in sciatic nerve action potential amplitude at minute intervals after death.(ABSTRACT TRUNCATED AT 250 WORDS)
